Subscribe: iTunes / Spotify
In this episode of Just Bold Enough, Teymour and Felicia discuss the innovative biotech company Syntis and its potential impact on obesity treatment. Syntis has developed a pill that acts as a gastric bypass, blocking the absorption of glucose in the small intestine. The pill contains a polymer that reacts with an enzyme in the digestive tract, creating a barrier that sticks to the intestinal wall. This simple yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry. The team at Syntis, led by CEO Raul, is experienced and knowledgeable, and they are already ahead on their milestones, with human clinical trials underway. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatment and make it more accessible to those who need it.
Story Notes:
- Addressing the Obesity Challenge
- Navigating the Regulatory Landscape
- The Potential Impact on the Pharmaceutical Industry
To learn more, visit:
https://boldcapitalpartners.com/
